This document is scheduled to be published in the Federal Register on 11/14/2016 and available online at https://federalregister.gov/d/2016-27222, and on FDsys.gov

[Billing Code 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S.

Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209

and 37 CFR Part 404 to achieve expeditious commercialization of federally-funded

research and development. Foreign patent applications are filed on selected inventions to

extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of

the U.S. patent applications listed below may be obtained by writing to the indicated

licensing contact at the National Heart, Lung and Blood Institute, Office of Technology

Transfer and Development, National Institutes of Health, 31 Center Drive Room 4A29,

MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential

Disclosure Agreement may be required to receive copies of the patent applications.

1

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Immortalized Organ of Corti Cell Line OC-k3

Description of Technology:

Available for nonexclusive licensing as a research material is a conditionally

immortalized Organ of Corti cell line called OC-k3. Sensory cells from the auditory

organ, the Organ of Corti, are terminally differentiated and cannot be cultured.

Moreover, few of them can be isolated per cochlea and survive only few hours after

isolation making impossible to use on them many biochemical and molecular biology

techniques. OC-k3, expresses many markers of sensory cells and it has already been used

as an in vitro model for a variety of studies.

Potential Commercial Applications:

Research

• Hearing research

• Susceptibility to ototoxic drugs

Development Stage:

• Materials

Inventors: Gilda Mabel Canseco de Kalinec and Federico Kalinec (both of

NIDCD).

Publications:

1. Bertolaso L, et al. (2001) "Apoptosis in the OC-k3 immortalized cell line treated

with different agents." Audiology 40:327-335. PMID: 1178104637-5745.

2

2. Previati M, et a. (2007) "Cisplatin cytotoxicity in Organ of Corti -derived immortalized cells." *J Celt Biochem*. 101(5):1185-97, PMID: 7243113.

Intellectual Property: HHS Reference No. E-012-2017/0 – Research Material.

Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;

shmilovm@mail.nih.gov.

Dated: November 7, 2016

g_____

Michael Shmilovich

National Heart, Lung and Blood Institute

Office of Technology Transfer and Development

National Institutes of Health

[FR Doc. 2016-27222 Filed: 11/10/2016 8:45 am; Publication Date: 11/14/2016]